HealthcareServices

Cholangiocarcinoma Market Anticipated to Record Steady Gains, Advancing to $1.14 Billion by 2030

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cholangiocarcinoma market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Cholangiocarcinoma Market?

The cholangiocarcinoma market size has seen rapid expansion in recent years. It is forecast to grow from $0.62 billion in 2025 to $0.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.1%. The historical increase in the market can be linked to the rising occurrence of bile duct cancers, the restricted availability of curative treatments, the integration of chemotherapy as a standard approach, the proliferation of oncology treatment facilities, and the expanding array of oncology drug candidates.

The market for cholangiocarcinoma is anticipated to experience substantial expansion over the coming years. This market is projected to reach a valuation of $1.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.8%. Factors driving this growth during the forecast period include the increasing creation of targeted oncology medications, the growing adoption of personalized medicine strategies, the broadened scope of clinical trials for rare cancers, augmented investment in oncology studies, and a heightened emphasis on diagnosing the condition at an early stage. Key trends anticipated in the forecast period encompass a greater acceptance of targeted drug treatments, the escalating use of combination chemotherapy protocols, an intensified focus on precision oncology, the broadening of immunotherapy research, and a reinforced emphasis on early detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21139&type=smp

What Drivers Are Supporting Technological Adoption In The Cholangiocarcinoma Market?

The rising occurrence of liver disease is anticipated to drive the expansion of the cholangiocarcinoma market in the future. Liver disease encompasses conditions that disrupt the liver’s normal functioning or structure, such as hepatitis, cirrhosis, fatty liver disease, and liver cancer. The frequency of liver disease is escalating because of a rise in risk factors including obesity, diabetes, alcohol intake, and viral hepatitis infections. Specifically, chronic inflammation and cirrhosis, both forms of liver disease, elevate the risk of cholangiocarcinoma through fostering damage to the bile ducts and encouraging malignant cell changes. For example, data from the Office for Health Improvement and Disparities, a UK government body, indicated that in December 2024, premature fatalities stemming from alcoholic liver disease saw an increase of 3.6% in 2023, reaching 5,984 compared to 5,776 in 2022. Consequently, the growing incidence of liver disease is fueling expansion within the cholangiocarcinoma market.

Which Segments Are Contributing To The Growth Of The Cholangiocarcinoma Market?

The cholangiocarcinoma market covered in this report is segmented –

1) By Cancer: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma

2) By Product: Capecitabine, 5-Fluorouracil, Oxaliplatin, Gemcitabine, Cisplatin

3) By Therapy: Targeted Drug Therapy, Chemotherapy, Immunotherapy

4) By Route Of Administration: Oral, Subcutaneous, Intravenous

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, E-Commerce

Subsegments:

1) By Intrahepatic Cholangiocarcinoma: Peripheral Intrahepatic Cholangiocarcinoma, Mass-Forming Intrahepatic Cholangiocarcinoma

2) By Extrahepatic Cholangiocarcinoma: Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma

Which Trends Are Influencing The Development Of The Cholangiocarcinoma Market?

Major companies within the cholangiocarcinoma market are concentrating on developing innovative treatments, such as targeted therapies, to enhance patient treatment outcomes. Targeted therapies are specifically formulated to address particular genes, proteins, or molecules that facilitate the growth of cancer cells. These treatments operate by disrupting the mechanisms that enable cancer to proliferate, with the goals of inhibiting tumor expansion, lessening side effects, and bettering overall treatment results. For example, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, introduced LYTGOBI (futibatinib), an FGFR inhibitor, for managing unresectable biliary tract cancer presenting with FGFR2 gene fusions. This medication is engineered to selectively and irreversibly suppress FGFR signaling, aiding in the deceleration of tumor growth and improving prognoses for patients with cholangiocarcinoma (iCCA) whose disease has advanced following chemotherapy.

Who Are The Prominent Global Companies Shaping The Cholangiocarcinoma Market Landscape?

Major companies operating in the cholangiocarcinoma market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boston Scientific Corporation, Servier Laboratories, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Agios Pharmaceuticals Inc., RenovoRx Inc., Specialised Therapeutics Pty Ltd, Ascletis Pharma Inc., Tiziana Life Sciences Ltd., Taiho Pharmaceutical Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cholangiocarcinoma-global-market-report

Which Region Currently Holds The Largest Share Of The Cholangiocarcinoma Market?

North America was the largest region in the cholangiocarcinoma market in 2025. The regions covered in the cholangiocarcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cholangiocarcinoma Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21139&type=smp

Browse Through More Reports Similar to the Global Cholangiocarcinoma Market 2026, By The Business Research Company

Invasive Ductal Carcinoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Gastrointestinal Stromal Tumor Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Liver Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795